Barclays upgraded Emerson (EMR) to Equal Weight from Underweight with a price target of $127, up from $125, following the Q3 report. The firm believes the process markets will be “fairly steady” into 2026. Market expectations for Emerson’s process and industrial capex outlook now appear more realistic, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EMR: